Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer

Seung Woo Yi, Dae Ryong Kang, Kyung Sik Kim, Mi Suk Park, Jinsil Seong, Jeong Youp Park, Seung Min Bang, Si Young Song, Jae Bock Chung, Seung Woo Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). Methods: We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. Results: Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85-49.30) in CCRT group and 13.29 weeks (95 % CI 10.42-16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed. Conclusions: Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages.

Original languageEnglish
Pages (from-to)191-198
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume73
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

gemcitabine
Chemoradiotherapy
Biliary Tract Neoplasms
Fluorouracil
Toxicity
Survival
Confidence Intervals
Republic of Korea
Therapeutics
Nausea
Anemia
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Yi, Seung Woo ; Kang, Dae Ryong ; Kim, Kyung Sik ; Park, Mi Suk ; Seong, Jinsil ; Park, Jeong Youp ; Bang, Seung Min ; Song, Si Young ; Chung, Jae Bock ; Park, Seung Woo. / Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. In: Cancer Chemotherapy and Pharmacology. 2014 ; Vol. 73, No. 1. pp. 191-198.
@article{4ed6326f4bac457cafc6e294ee52c6e5,
title = "Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer",
abstract = "Purpose: There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). Methods: We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. Results: Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 {\%} confidence interval [CI], 35.85-49.30) in CCRT group and 13.29 weeks (95 {\%} CI 10.42-16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed. Conclusions: Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages.",
author = "Yi, {Seung Woo} and Kang, {Dae Ryong} and Kim, {Kyung Sik} and Park, {Mi Suk} and Jinsil Seong and Park, {Jeong Youp} and Bang, {Seung Min} and Song, {Si Young} and Chung, {Jae Bock} and Park, {Seung Woo}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00280-013-2340-5",
language = "English",
volume = "73",
pages = "191--198",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. / Yi, Seung Woo; Kang, Dae Ryong; Kim, Kyung Sik; Park, Mi Suk; Seong, Jinsil; Park, Jeong Youp; Bang, Seung Min; Song, Si Young; Chung, Jae Bock; Park, Seung Woo.

In: Cancer Chemotherapy and Pharmacology, Vol. 73, No. 1, 01.01.2014, p. 191-198.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer

AU - Yi, Seung Woo

AU - Kang, Dae Ryong

AU - Kim, Kyung Sik

AU - Park, Mi Suk

AU - Seong, Jinsil

AU - Park, Jeong Youp

AU - Bang, Seung Min

AU - Song, Si Young

AU - Chung, Jae Bock

AU - Park, Seung Woo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). Methods: We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. Results: Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85-49.30) in CCRT group and 13.29 weeks (95 % CI 10.42-16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed. Conclusions: Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages.

AB - Purpose: There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC). Methods: We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival. Results: Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85-49.30) in CCRT group and 13.29 weeks (95 % CI 10.42-16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed. Conclusions: Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages.

UR - http://www.scopus.com/inward/record.url?scp=84892805407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892805407&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2340-5

DO - 10.1007/s00280-013-2340-5

M3 - Article

AN - SCOPUS:84892805407

VL - 73

SP - 191

EP - 198

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -